Strategies to accomplish targeted gene delivery to muscle cells employing tropism-modified adenoviral vectors

Neuromuscular Disorders

Volumn 7, Issue 5, 1997, Pages 284-298

  Douglas, Joanne T ^a   Curiel, David T ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Adenovirus vectors; Gene therapy; Muscle cells

Indexed keywords

FOLIC ACID; IMMUNOGLOBULIN F(AB) FRAGMENT; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; CHIMERA; CONJUGATION; DNA RECOMBINATION; DUCHENNE MUSCULAR DYSTROPHY; GENE TARGETING; GENE THERAPY; HUMAN; MUSCLE CELL; NONHUMAN; PLASMID; PRIORITY JOURNAL; VIRUS DNA CELL DNA INTERACTION;

ADENOVIRIDAE; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; GENE TARGETING; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MUSCLES; TROPISM;

EID: 0030850681     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-8966(97)00053-9     Document Type: Article

References (98)

1. Hoffman E, Brown R, Kunkel L. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987;51:919-928.
2. Koenig M, Hoffman E, Bertelson C, Monaco A, Feener C, Kunkel L. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organisation of the DMD gene in normal and affected individuals. Cell 1987;50:509-517.
3. Karpati G, Ascadi G. The potential for gene therapy in Duchenne muscular dystrophy and other genetic muscle diseases. Muscle Nerve 1993;16:1141-1153.
4. Partridge T. Myoblast transfer: a possible therapy for inherited myopathies. Muscle Nerve 1991;14:197-212.
5. Ascadi G, Dickson G, Love D, et al. Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. Nature 1991;352:815-818.
6. Wolff J, Williams P, Ascadi G, Jiao S, Jani A, Chong W. Conditions affecting direct gene transfer into rodent muscle in vivo. Biotechnology 1991;11:474-485.
7. Jiao S, Williams P, Berg R, et al. Direct gene transfer into nonhuman primate myofibers in vivo. Hum Gene Ther 1992;3:21-33.
8. Davis H, Whalen R, Demeneix B. Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression. Hum Gene Ther 1993;4:151-159.
9. Dunckley M, Wells D, Walsh F, Dickson G. Direct retroviral-mediated transfer of a dystrophin minigene into mdx mouse muscle in vivo. Hum Mol Genet 1993;2:717-723.
10. Kass-Eisler A, Falck-Pedersen E, Alvira M, et al. Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo. Proc Natl Acad Sci USA 1993;90:11498-11502.
11. Ragot T, Vincent N, Chafey P, et al. Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature 1993;361:647-650.
12. Vincent N, Ragot T, Gilgenkrantz H, et al. Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene. Nat Genet 1993;5:130-134.
13. Stratford-Perricaudet L, Makeh I, Perricaudet M, Briand P. Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest 1992;90:626-630.
14. Jaffe H, Danel C, Longenecker G, et al. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat Genet 1992;1:372-378.
15. Lemarchand P, Jones M, Yamada I, Crystal R. In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Res 1993;72:1132-1138.
16. Kay M, Landen C, Rothenberg S, et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 1994;91:2353-2357.
17. Herz J, Gerard R. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA 1993;90:2812-2816.
18. Ishibashi S, Brown M, Goldstein J, Gerard R, Hammer R, Herz J. Hypercholesterolemia in low density lipoprotein knockout mice and its reversal by adenovirus-mediated gene delivery. Clin Invest 1993;92:883-893.
19. Kozarsky K, McKinley D, Austin L, Raper S, Stratford-Perricaudet L, Wilson J. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem 1994;269:13695-13702.
20. Quantin B, Perricaudet L, Tajbakhsh S, Mandel J-L. Adenovirus as an expression vector in muscle cells in vivo. Proc Natl Acad Sci USA 1992;89:2581-2584.
21. Brown D, Bulingham B. Penetration of host cell membranes by adenovirus 2. J Virol 1973;12:386-396.
22. Svensson U, Persson R. Entry of adenovirus 2 into HeLa cells. J Virol 1984;51:687-694.
23. Varga M, Weibull C, Everitt E. Infectious entry pathway of adenovirus type 2. J Virol 1991;65:6061-6070.
24. Huard J, Lochmüller H, Ascadi G, Jani A, Massie B, Karpati G. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther 1995;2:107-115.
25. Engelhardt J, Simon R, Yang Y, et al. Adenovirus-mediated transfer of the CFTR gene to lung of non-human primates: Biological efficacy study. Hum Gene Ther 1993;4:759-769.
26. Simon R, Engelhardt J, Yang Y, et al. Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: Toxicity study. Hum Gene Ther 1993;4:771-780.
27. Yang Y, Nunnes F, Berencsi K, Furth E, Gonczol E, Wilson J. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994;91:4407-4411.
28. Yei S, Mittereder N, Wert S, Whitsett J, Wilmont R, Trapnell B. In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. Hum Gene Ther 1994;5:731-744.
29. Engelhardt J, Litzky L, Wilson J. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum Gene Ther 1994;5:1217-1229.
30. Engelhardt J, Ye X, Doranz B, Wilson J. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994;91:6196-6200.
31. Yang Y, Nunes F, Berencsi K, Gonczol E, Engelhardt J, Wilson J. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994;7:362-369.
32. Lochmüller H, Petrof B, Allen C, Prescott S, Massie B, Karpati G. Immunosuppression by FK506 markedly prolongs expression of adenovirus-delivered transgene in skeletal muscles of adult dystrophic [mdx] mice. Biochem Biophys Res Commun 1995;213:569-574.
33. Tripathy S, Black H, Goldwasser E, Leiden J. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996;2:545-550.
34. Phelps S, Hauser M, Cole N, et al. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 1995;4:1251-1258.
35. Wells D, Wells K, Asante E, et al. Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy. Hum Mol Genet 1995;4:1245-1250.
36. Anderson W. Human gene therapy. Science 1992;256:808-813.
37. Douglas J, Curiel D. Targeted gene therapy. Tumor Targeting 1995;1:67-84.
38. Weiss R, Boettiger D, Murphy H. Pseudotypes of avian sarcoma viruses with the envelope properties of vesicular stomatitis virus. Virology 1977;76:808-825.
39. Roux P, Jeanteur P, Piechaczyk M. A versatile and potentially general approach to the targeting of specific cell types by retroviruses: application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses. Proc Natl Acad Sci USA 1989;86:9079-9083.
40. Emi N, Friedmann T, Yee J-K. Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus. J Virol 1991;65:1202-1207.
41. Neda H, Wu C, Wu C. Chemical modification of an ecotropic murine leukemia virus results in redirection of its target cell specificity. J Biol Chem 1991;266:14143-14146.
42. Etienne-Julan M, Roux P, Carillo S, Jeanteur P, Piechaczyk M. The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker. J Gen Virol 1992;73:3251-3255.
43. Kasahara N, Dozy A, Kan Y. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 1994;266: 1373-1376.
44. Valsesia-Wittmann S, Drynda A, Deleage G, et al. Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J Virol 1994;68:4609-4619.
45. Chu T-H, Dornburg R. Retroviral vector particles displaying the antigen-binding site of an antibody enable cell-type-specific gene transfer. J Virol 1995;69:2659-2663.
46. Cosset F-L, Morling F, Takeuchi Y, Weiss R, Collins M, Russell S. Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol 1995;69:6314-6322.
47. Han X, Kasahara N, Kan Y. Ligand-directed retroviral targeting of human breast cancer cells. Proc Natl Acad Sci USA 1995;92:9747-9751.
48. Somia N, Zoppe M, Verma I. Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. Proc Natl Acad Sci USA 1995;92:7570-7574.
49. Marin M, Noel D, Valsesia-Wittmann S, et al. Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins. J Virol 1996;70:2957-2962.
50. Valsesia-Wittmann S, Morling F, Nilson B, Takeuchi Y, Russell S, Cosset F-L. Improvement of retroviral retargeting by using amino acid spacers between an additional binding domain and the N-terminus of Moloney murine leukemia virus SU. J Virol 1996;70:2059-2064.
51. Seth P, FitzGerald D, Willingham M, Pastan I. Pathway of adenovirus entry into cells. In: Crowell R, Lonberg-Holm K, eds. Virus Attachment and Entry into Cells. Washington, DC: American Society for Microbiology, 1986:191-195.
52. Philipson L, Lonberg-Holm K, Pettersson U. Virus-receptor interaction in an adenovirus system. J Virol 1968;2:1064-1075.
53. Wickham T, Mathias P, Cheresh D, Nemerow G. Integrins avb3 and avb5 promote adenovirus internalisation but not virus attachment. Cell 1993;73:309-319.
54. Defer C, Belin M-T, Caillet-Boudin M-L, Boulanger P. Human adenovirus-host cell interactions: comparative study with members of subgroups B and C. J Virol 1990;64:3661-3673.
55. vanOostrum J, Burnett R. Molecular composition of the adenovirus type 2 virion. J Virol 1985;56:439-448.
56. Ruigrok R, Barge A, Albiges-Rizo C, Dayan S. Structure of adenovirus fiber. II. Morphology of single fibres. J Mol Biol 1990;215:589-596.
57. Boudin M-L, Boulanger P. Assembly of adenovirus penton base and fiber. Virology 1982;116:589-604.
58. Stewart P, Burnett R, Cyrlaff M, Fuller S. Image reconstruction reveals the complex molecular organisation of adenovirus. Cell 1991;67:145-154.
59. Stewart P, Fuller S, Burnett R. Difference imaging of adenovirus: bridging the resolution gap between X-ray crystallography and electron microscopy. EMBO J 1993;12:2589-2599.
60. Green N, Wrigley N, Russell W, Martin S, McLachlan A. Evidence for a repeating cross-b sheet structure in the adenovirus fiber. EMBO J 1983;2:1357-1365.
61. Henry L, Xia D, Wilke M, Deisenhofer J, Gerard R. Characterisation of the knob domain of the adenovirus type 5 fiber protein expressed in E. coli. J Virol 1994;68:5239-5246.
62. Louis N, Fender P, Barge A, Kitts P, Chroboczek J. Cell-binding domain of adenovirus serotype 2 fiber. J Virol 1994;68:4104-4106.
63. Chardonnet Y, Dales S. Early events in the interaction of adenoviruses with HeLa cells. Virology 1970;40:462-477.
64. FitzGerald D, Padmanabhan R, Pastan I, Willingham M. Adenovirus-induced release of epidermal growth factor and Pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis. Cell 1983;32:607-617.
65. Greber U, Willetts M, Webster P, Helenius A. Stepwise dismantling of adenovirus 2 during entry into cells. Cell 1993;75:477-486.
66. Bai M, Harfe B, Freimuth P. Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells. J Virol 1993;67:5198-5205.
67. 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. J Virol 1995;69:2257-2263.
68. Michael S, Huang C, Romer M, Wagner E, Hu P, Curiel D. Binding-incompetent adenovirus facilitates molecular conjugate-mediated gene transfer by the receptor-mediated endocytosis pathway. J Biol Chem 1993;268:6866-6869.
69. Michael S, Hong J, Curiel D, Engler J. Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther 1995;2:660-669.
70. Hong J, Engler J. The amino terminus of the adenovirus fiber protein encodes the nuclear localisation signal. Virology 1991;185:758-767.
71. Novelli A, Boulanger P. Deletion analysis of functional domains in baculovirus-expressed adenovirus type 2 fiber. Virology 1991;185:365-376.
72. Novelli A, Boulanger P. Assembly of adenovirus type 2 fiber synthesised in cell-free translation system. J Biol Chem 1991;266:9299-9303.
73. Batley J, Wada E. Two distinct receptor subtypes for mammalian bombesin-like peptides. Trends Neurosci 1991;14:524-528.
74. McGrory W, Bautista D, Graham F. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 1988;163:614-617.
75. Ghosh-Choudhury G, Haj-Ahmad Y, Graham F. Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of full length genomes. EMBO J 1987;6:1733-1739.
76. Bett A, Haddara W, Prevec L, Graham F. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994;91:8802-8806.
77. Falgout B, Ketner G. Characterisation of adenovirus particles made by deletion mutants lacking the fiber gene. J Virol 1988;62:622-625.
78. Mittal S, McDermott M, Johnson D, Prevec L, Graham F. Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter. Virus Res 1993;28:67-90.
79. Krasnykh V, Mikheeva G, Douglas J, Curiel D. Generation of tropism-modified adenoviral vectors with modified fibers for altering viral tropism. Submitted for publication.
80. Stevenson S, Rollence M, White B, Weaver L, McClelland A. Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. J. Virol 1995;69:2850-2857.
81. Douglas J, Rogers B, Rosenfeld M, Michael S, Feng M, Curiel D. Targeted gene delivery by tropism-modified adenoviral vectors. Submitted for publication.
82. Leamon C, Low P. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci USA 1991;88:5572-5576.
83. Leamon CP, Low PS. Cytotoxicity of momordin-folate conjugates in cultured human cells. J Biol Chem 1992;267:24966-24971.
84. Leamon CP, Pastan I, Low PS. Cytotoxicity of folate-Pseudomonas exotoxin conjugates toward tumor cells. Contribution of translocation domain. J Biol Chem 1993;268:24847-24854.
85. Turek JJ, Leamon CP, Low PS. Endocytosis of folate-protein conjugates: ultrastructural localisation in KB cells. J Cell Sci 1993;106:423-430.
86. Gottschalk S, Cristiano R, Smith L, Woo S. Folate receptor mediated DNA delivery into tumor cells: potosomal disruption results in enhanced gene expression. Gene Ther 1994;1:185-191.
87. Lee RJ, Low PS. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem 1994;269:3198-3204.
88. Kranz D, Patrick T, Brigle K, Spinella M, Roy E. Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis. Proc Natl Acad Sci USA 1995;92:9057-9061.
89. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochem Biophys Acta 1995;1233:134-144.
90. Anderson R, Kamen B, Rothberg K, Lacey S. Potocytosis: sequestration and transport of small molecules by caveolae. Science 1992;255:410-411.
91. Elwood P. Molecular cloning and characterisation of the human folate-binding protein cDNA from placenta and malignant tissue culture (KB) cells. J Biol Chem 1989;264:14893-14901.
92. Russell S, Hawkins R, Winter G. Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res 1993;21:1081-1085.
93. Barry M, Dower W, Johnston S. Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat Med 1996;2:299-305.
94. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996;380:364-366.
95. Ascadi G, Jani A, Massie B, et al. A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity. Hum Mol Genet 1994;3:579-584.
96. Ascadi G, Jani A, Huard J, et al. Cultured human myoblasts and myotubes show markedly different transducibility by replication-defective adenovirus recombinants. Gene Ther 1994;1:338-340.
97. Wickham T, Carrion M, Kosvedi I. Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Ther 1995;2:750-756.
98. Mathias P, Wickham T, Moore M, Nemerow G. Multiple adenovirus serotypes use as integrins for infection. J Virol 1994;68: 6811-6814.